UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41875 | --- | --- | --- | |-------------------------------------------------------|------------------------------------------------------------------------------- ...

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme. Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator. Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. "Dr. Shirihai is recognized ...

Orian Shirihai, MD, PhD, is currently a Professor of Medicine at the University of California, Los Angeles (UCLA) where he serves as Director of the UCLA Metabolism Research Theme. The Shirihai laboratory focuses on mitochondrial structure, function and quality control, making key contributions to mitochondrial biology including the discovery of the life cycle of the mitochondria and the relationship between mitochondrial architecture and nutrient utilization in metabolic diseases. Another focus of the Shir ...

· ® NEXTGENERATION SKIN&SCALPREJUVENATION: STEM CELL EXOSOMES + MITOCHONDRIAL BIOGENESIS TECHNOLOGY DISCOVERED USING AI 2 Jordan R. Plews, PhD Biochemical Engineer & Stem Cell Scientist. Academic research completed at University College London, University of Sheffield, and Stanford University. AGSTANT CONTINUES COLLEGE 3 Cofounder of ELEVAI Labs Inc. (Nasdaq: ELAB) CEO of ELEVAI Skincare Inc. Experience with human stem cells, molecular biology, single cell genomics, proteomics, RNA analysis, as well as cell ...

Elevai's hair and scalp solutions combine the power of Exosomes with advanced Mitochondrial Technology. The Elevai S-series Root Renewal System™ and the technology behind it will be presented at The Aesthetic Show on June 28th, 2024, held at the Wynn Las Vegas, NV. The Y100 mitochondrial technology was identified using Yuva's advanced artificial intelligence ("AI") platform, "MitoGPT" which was co-developed by Yuva Biosciences's Chief Scientific Officer, Keshav K. Singh, PhD and key advisor for AI, Jeb Lint ...

Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com. Forward-Looking Statements Statements contained in this press release regarding matters ...

NEWPORT BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced that Chief Executive Officer Jordan R. Plews, PhD has been invited back and will be presenting at the Beauty Through Science conference in Stockholm, Sweden on Thursday May 30, 2024. Beauty Through Science (BTS) is an annual event that gathers the greatest minds in aesthetic medicine to share the most up-to-date, innovative techniques and tec ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41875 | ELEVAI LABS INC. | | --- | (Exact name of registrant as specified in its charter) | Delaware | | 85-1399981 | | --- | --- | --- | | (State of incorporati ...

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1.Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.Elevai plans to submit an Investigatio ...

Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc.Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development of EL-22 and EL-32, the lead assets targeting indications associated with obesity.Elevai Skincare will continue commercializing exosome skincare technologies for the medical dispensed skincare market. NEWPORT BEACH, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("E ...